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Summary 
Background 
  Recently, germ-line mutations of aryl hydrocarbon receptor-interacting protein (AIP) 
gene located on 11q13 were identified in patients with pituitary adenoma predisposition. 
Aim/ Patients and Methods 
  We investigated the involvement of the AIP gene in one family with isolated familial 
somatotropinomas (IFS). To investigate the role of AIP in sporadic GH-secreting adenomas, 
we first analyzed somatic mutations in 40 tumours.  Second, DNA from corresponding 
leukocytes was analyzed in tumours showing genetic changes of the AIP gene. 
Results 
  Germ-line mutation of AIP was found in an IFS family.  Biallelic inactivation of AIP by 
a combination of germ-line mutation and loss of heterozygosity was confirmed in two 
pituitary adenomas.  Mutation analysis of the AIP gene in the 40 sporadic GH-secreting 
adenomas showed no mutations except for a missense mutation, suggesting that germ-line 
mutations in patients diagnosed with sporadic acromegaly or gigantism were rare.  In a 
patient with gigantism, a missense mutation of V49M was identified at the germ-line level.  
Conclusion 
  Based on these results, we conclude that the loss of function of AIP contributes to IFS, 
but not for most Japanese sporadic GH-secreting adenomas.  
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Introduction  
  Pituitary tumours are usually sporadic, but a significant minority presents as a 
component of multiple endocrine neoplasia type 1 (MEN1), Carney Complex (CNC), and 
isolated familial somatotropinomas (IFS).  
  IFS is defined as the occurrence of the at least two cases of acromegaly or gigantism in a 
single family in the absence MEN1 or CNC feature.1  Recently, Vierimaa et al.2 identified 
three germ-line mutations of the aryl hydrocarbon receptor-interacting protein (AIP) gene 
located on 11q13 in patients with pituitary adenoma predisposition (PAP).  PAP was 
defined as having a very-low-penetrance susceptibility to GH-secreting adenoma and 
prolactinoma.  Loss of heterozygosity (LOH) analysis in germ-line mutation positive 
GH-secreting adenomas, prolactinomas and mixed-type adenomas showed that both alleles 
of the AIP gene were inactivated.  In a population-based study, germ-line mutations in the 
AIP gene were found in 16% of patients with sporadic GH-secreting pituitary adenomas.  
Furthermore, 40% of patients aged younger than 35 years had an AIP mutation.  These 
results prompted us to analyze the germ-line mutation of the AIP gene in a Japanese IFS 
family and patients with sporadic acromegaly. 
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Patients and Methods 
Case presentation of IFS 
  The clinical findings in one pedigree of IFS (family A) were previously reported.3  
Briefly, two of three brothers (II-2 and II-3 in Figure 1) and their uncle (I-3) presented 
acromegaly or gigantism. The LOH at 11q13 was detected in two adenomas (a 
GH-secreting adenoma from II-2 and a mixed GH cell and PRL cell adenoma from II-3), 
but germ-line mutations of MEN1 gene were not detected.4  Written informed consent was 
obtained from each patient, and the protocol was approved by the ethics committees of 
Toranomon Hospital and The University of Tokushima. 
 
Sporadic GH-secreting adenomas patients  
  Tumour tissue samples were collected from 40 unselected patients with sporadic 
GH-secreting adenomas operated on at Toranomon Hospital, Tokyo.  Clinical information 
on 40 patients with acromegaly or gigantism is described in Table 1.  They had no family 
histories of pituitary adenomas.  Blood samples were also obtained.  Fully informed 
consent was obtained in accordance with institutional guidelines.   
 
DNA extraction 
  Tumour and normal tissues were separated under a microscope by cutting them into 
small pieces using a razor blade.  We microscopically confirmed that tumour tissues were 
scarcely contaminated with normal tissues.  Small pieces of tumours and peripheral 
leukocytes were treated with proteinase K.  Genomic DNA was obtained after 
phenol-chloroform extraction and ethanol precipitation.  
 5 
 
Primer design of the AIP gene 
  The nucleotide sequences of primers for the AIP1 gene accorded to the reports of 
Vierimaa et al..2  Mutations of the AIP gene were screened for 5 overlapping PCR 
products with the corresponding primer sets covering the entire coding region and splice 
junctions.   
 
PCR and sequence analysis 
  Genomic DNA was subjected to 30 cycles of PCR.  PCR cycle involved a denaturation 
step at 95 °C for 30 s, annealing step at 65 °C for 30 s, and extension step at 72 °C for 60 s.  
Samples were subjected to direct sequencing in sense and antisense directions. 
  In sporadic GH-secreting adenomas showing genetic changes, the DNA from 
corresponding leukocytes was analyzed.   
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Results  
Germ-line mutation of the AIP gene in an IFS family 
  Direct sequencing of leukocyte DNA PCR products from an IFS family detected a 
mutation of c.286_287delGT on exon 3.  The mutation resulted in a frameshift, leading to 
a change with proline 96 as the first affected amino acid and the new reading frame being 
open for 32 amino acids.  The mutation was found not only in affected members (I-3, II-2, 
and II-3 in Figure 1), but also in unaffected members (I-2 and II-1).  The mutation was not 
detected in an unaffected family member (I-1) or 50 normal Japanese individuals.   
  
Biallelic inactivation of the AIP gene in two pituitary adenomas from family A 
  In addition to the germ-line mutation, loss of the wild-type allele was observed in the 
two pituitary adenomas.  The co-presence of germ-line mutation and LOH showed the 
biallelic inactivation of the AIP gene in the tumours. 
 
Mutations of the AIP gene in sporadic GH-secreting adenomas 
  Sequencing of genomic DNA from 40 sporadic GH-secreting adenomas revealed no 
somatic mutations of the AIP gene.  However, we detected a polymorphism of c.516C>T 
on exon 4 (NCBI reference SNP ID number rs2276020) in 12 patients.  Furthermore, three 
nucleotide changes of c.135C>T, c.145G>A, and c.1053G>C were found in the respective 
leukocyte DNA.  A silent nucleotide change of c.135C>T on exon 2 was detected in one 
patient (No. 34 in Table 1).  The c.135C>T was not detected in 191 normal Japanese 
individuals, suggesting a possibility of single nucleotide polymorphism (SNP) with low 
frequency.  A silent nucleotide change of c.1053G>C on the 3’-noncoding region was 
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detected in two patients (No. 16 and 37 in Table 1).  The c.1053G>C was detected in 6 
alleles among 50 normal Japanese individuals, suggesting a SNP.  A 28-year-old male 
with gigantism (No. 35 in Table 1) showed a missense mutation of c.145G>A (V49M) at 
the germ-line level.  The c.145G>A was not detected in 191 normal Japanese individuals.   
He did not have an apparent family history of GH-secreting adenomas.  In his 
GH-secreting adenoma, a wild-type allele of the AIP gene was retained.   
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Discussion 
  Most of the molecular mechanisms involved in the genesis of pituitary adenomas have 
not been uncovered.  In IFS, LOH at 11q13 in pituitary adenomas was detected and no 
MEN1 germ-line mutations were identified.3, 4, 5  Based on these results, the disease locus 
for IFS appears to exist within the region of approximately 2.21 Mb on 11q13.3.5  
Recently, germ-line mutations of the AIP gene were identified in patients with PAP.2  A 
nonsense mutation of Q14X in exon 1 was segregated with the GH-secreting adenoma 
phenotype in two Finnish PAP families.  One pedigree with 3 patients of IFS in our study 
against the total number of only 46 reported pedigrees1 afforded us an important 
opportunity to screen germ-line mutations of the AIP gene. 
  The mutation of c.286_287delGT was detected in three patients with acromegaly or 
gigantism and a healthy mother and brother (I-2 and II-1 in Figure 1) with normal serum 
levels of GH and IGF1.  This is consistent with the result of haplotype analysis on 11q13 
in family members.3  IFS is inherited as an autosomal dominant disease with incomplete 
penetrance.  Vierimaa et al.2 reported that newly identified AIP mutations leading to PAP 
show low penetrance.  A precise estimate of the age-related penetrance of AIP mutation 
requires information from a large number of families. 
  The co-presence of germ-line mutation and LOH at the AIP gene in two pituitary 
adenomas from one IFS family suggested that the loss of function of AIP contributed to IFS.   
Interestingly, the mixed GH and prolactin adenoma from II-3 showed somatic inactivation 
of MEN1 with c.1682delA and LOH,4 suggesting the inactivation of two tumour suppressor 
genes, AIP and MEN1, in the tumour.  
  AIP displays primary sequence homology with the FK506-binding protein family of 
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immunophilins.6  AIP can interact with both Hsp90 and aryl hydrocarbon receptor (AhR), 
which leads to enhanced stability of the complex.7  The AhR is a ligand-activated 
transcription factor that is a member of the basic helix-loop-helix Per/ARNT/Sim family.  
The AIP acts as a modulator to differentially regulate AhR activity possibly by regulating 
the levels of p23 incorporation in the AhR complex.8  AIP is known to inhibit a 
phosphodiesterase,9 linking AIP to cyclic AMP.  AIP directly associates with survivin, 
which is a member of the inhibitor of apoptosis family.10  The knock down of AIP 
destabilizes survivin levels.  Thus, it has been thought that AIP has oncogenic activity; 
however, the function of AIP as a tumour suppressor protein has not been reported. 
Because AhR arrests cell cycle through activation of p27 and repression of cyclin E,11 AIP 
may be related to cell cycle regulation.  Molecular mechanisms of AIP as tumour 
suppressor proteins remain to be elucidated.   
  The most prominent molecular lesions are point mutations in the GNAS1, which occurs 
in up to 50 per cent of GH-secreting adenomas.12, 13  Inactivation of MEN1 and PRKAR1A 
in sporadic pituitary adenomas, including GH-secreting adenomas, was reported to be 
infrequent events.13, 14, 15, 16  Thus, molecular pathogenesis of GH-secreting adenomas is 
largely unknown. 
  The population-based study in patients with 45 GH-secreting adenomas, including 4 
patients from 2 Finnish PAP families, found germ-line mutations in the AIP gene; 6 
patients had Q14X and one patient had IVS3-1G>A.2  Furthermore, Q14X was found in 2 
of 10 unselected Finnish sporadic acromegaly. 2  Based on these results, a role of the AIP 
gene in sporadic GH-secreting pituitary adenomas remains an important question.  
Mutation analysis of the AIP gene showed no somatic mutations in the 40 GH-secreting 
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adenomas.  In one patient with gigantism, a missense mutation of V49M was identified.  
Although a wild-type allele of the AIP gene was retained in the GH-secreting adenoma, it 
cannot be completely denied that lack of LOH was due to contaminated normal tissues.  
Whether V49M has a function as a tumour suppressor remains to be elucidated.  Although 
methylation-dependent inactivation or mutations in the promoter, introns or untranslated 
regions of the AIP gene were not excluded in our study, our results suggest that somatic 
inactivation of the AIP gene was not a common etiology of sporadic GH-secreting 
adenomas.  Furthermore, germ-line mutations of the AIP gene were found to be rare in 
Japanese patients diagnosed with sporadic GH-secreting adenomas compared to the results 
in Finland. 2   
  In the present study, a germ-line AIP mutation was detected in one IFS family and a 
GH-secreting adenoma and mixed GH and prolactin adenoma in the family showed null 
mutation of AIP; however, AIP somatic mutations or germ-line mutations, except for one 
missense mutation, were not detected in the 40 Japanese sporadic GH-secreting adenomas.  
We conclude that AIP does not play a significant role in the tumourigenesis of sporadic 
GH-secreting adenomas. 
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Figure legends 
Figure 1.  Pedigree of family A.  Family members are indicated by generation (Roman 
numerals) and individuals (Arabic numerals).  Individuals are represented as male 
(squares) and female (circles).  The proband is indicated by an arrow.  Closed symbols 
denote affected members.  Open symbols denote unaffected members.  Sequencing of the 
AIP gene showed a wild-type sequence (wt) or the presence of a mutation (mut).   
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Table 1 Cinical data of patients with sporadic GH-secreting adenomas 
Patient 
 No. Sex 
Age at  
diagnosis 
ＧＨ  
(µg/l) 
PRL  
(µg/l) 
Hardy's  
classification  
1 male 48 32.5  II-0 
2 male 71 38.2  I-0 
3 male 56 24  I-0 
4 male 32 14  I-0 
5 female 79 13  I-0 
6 female 54 795.2  III-C 
7 female 20 134.6  IV-B 
8 female 33 33.7 21.8 III-B 
9 female 31 2.2  III-B 
10 female 29 135.2  IV-B 
11 male 40 34.2  III-B 
12 female 41 29.1  IV-B 
13 female 26 16  III-C 
14 male 34 22  III-0 
15 female 26 23  II-0 
16 female 28 78  III-C 
17 female 65 4.7  I-0 
18 female 36 46 26.1 III-B 
19 male 42 11  III-0 
20 male 46 47  III-A 
21 male 38 80  III-A 
22 male 73 9  I-0 
23 male 25 78.5  II-A 
24 male 43 22  III-A 
25 male 59 67  II-A 
26 female 30 38  IV-B 
27 male 63 17  III-A 
28 male 28 60 38.3 III-A 
29 male 42 112  III-0 
30 female 45 5.7  II-0 
31 female 64 22  II-0 
32 male 48 43  III-0 
33 male 56 35.9  II-A 
34 female 67 104 42.4 III-0 
35 male 28 80 24.8 III-0 
36 male 63 7.8  I-0 
37 male 51 7.1  I-0 
38 male 47 370  III-0 
39 male 38 28 28 III-0 
40 female 70 25   III-A 
 
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